Serum Institute of India Pvt Ltd.
- Country
- 🇮🇳India
- Ownership
- Subsidiary
- Established
- 1996-01-01
- Employees
- 1K
- Market Cap
- -
Clinical Trials
71
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (69 trials with phase data)• Click on a phase to view related trials
An Observational Study to Assess Effectiveness and Safety of The R21/Matrix-M Malaria Vaccine
- Conditions
- Malaria,FalciparumMorality
- First Posted Date
- 2025-06-08
- Last Posted Date
- 2025-06-08
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 2308
- Registration Number
- NCT07009847
- Locations
- 🇧🇫
Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Sciences de la Santé, Direction Régionale du Centre-Ouest (IRSS-DRCO), Bousse, Boussé, Burkina Faso
🇨🇮Centre de Recherche et de Lutte contre le Paludisme Institut National de Santé Publique, boulevard Nangui Abrogoua près État Major des Armées, Toumodi, Côte D'Ivoire
🇳🇬University of Ilorin Department of Pediatrics University of Ilorin Teaching Hospital, Ilorin, Nigeria, Yenagoa, Bayesla, Nigeria
Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults
- Conditions
- Prevention of Malaria Transmission and Clinical Malaria
- Interventions
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT06507605
- Locations
- 🇲🇱
University of Science, Technique and Technology of Bamako (Usttb), Bamako, Mali
Clinical Study to Assess the Immunogenicity and Safety of Hexavalent Vaccine Containing Reduced Dose IPV
- Conditions
- Polio ImmunizationHepatitis B ImmunizationHaemophilus Influenzae Type B ImmunizationTetanus ImmunizationDiptheria ImmunizationPertussis Immunization
- Interventions
- Biological: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Full Dose IPVBiological: Hexavalent (DTwP-HepB-IPV-Hib) Vaccine Containing Reduced Dose IPV
- First Posted Date
- 2024-05-14
- Last Posted Date
- 2024-05-21
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 1557
- Registration Number
- NCT06413121
- Locations
- 🇧🇩
International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B), Dhaka, Bangladesh
🇮🇳Hamdard Institute of Medical Sciences and Research (HIMSR) with Centre for health research & Development, Society for applied studies, Hakeem Abdul Hameed Centenary Hospital (HAHCH), New Delhi, Delhi, India
🇮🇳Manipal Academy of Higher Education, Manipal, Mangalore, Karnataka, India
Clinical Study to Evaluate SIIPL QHPV Vaccine (CERVAVAC®) in Women Living with HIV Aged 15-25 Years
- Conditions
- Human Papillomavirus Infection
- Interventions
- Biological: Cervavac as two dose regimenBiological: Cervavac as three dose regimenBiological: Gardasil as three dose regimen
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2025-01-07
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06281119
- Locations
- 🇰🇪
Centre For Clinical Research, Kemri, Nairobi, Kenya
🇰🇪Partners in Health and Research Development (Phrd), Thika, Kenya
🇲🇿Manhiça Health Research Center - Manhiça Foundation (CISM-FM), Manhiça, Mozambique
A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy Infants
- Conditions
- Yellow Fever
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2023-11-28
- Lead Sponsor
- Serum Institute of India Pvt. Ltd.
- Target Recruit Count
- 2216
- Registration Number
- NCT05447377
- Locations
- 🇬🇲
MRC Unit The Gambia at LSHTM, Banjul, Gambia
🇲🇱Center for Vaccine Development, Bamako, Mali
- Prev
- 1
- 2
- 3
- 4
- 5
- Next